Aktuellt
SENASTE
Redeye's view continues to be that BioArctic's drug candidate lecanemab has a high likelihood of approval and the best clinical profile and dataset in the amyloid-beta space. We maintain our valuation and expect a commercial breakthrough after a potential full approval in the US once results from Clarity AD become available this fall.
LÄS MER
